
    
      Nimotuzumab and Docetaxel will be administered to the patient until disease progression or
      unacceptable toxicity had occurred.Docetaxel was administered every 3 weeks 75mg/m2;
      Nimotuzumab treatment at 200mg per week,at least 12 weeks.The patients'hematology and
      biochemistry examination will be monitored weekly, a physical exam and assessment of the
      tumor will be performed and every 6 weeks. The patients will be followed up every 3 months to
      evaluate the survival.
    
  